Premium
Decrease of the insulin‐like growth factor‐1 bioavailability in spontaneously hypertensive rats with erectile dysfunction
Author(s) -
Zhou Z.Y.,
Cheng S.P.,
Huang H.,
Sun Y.L.,
Xiao S.,
Liu R.H.,
Mao F.J.,
Zhong G.J.,
Huang J.B.,
Pan H.
Publication year - 2016
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/and.12518
Subject(s) - cyclic guanosine monophosphate , erectile dysfunction , medicine , endocrinology , bioavailability , guanosine , propranolol , insulin like growth factor , growth factor , chemistry , pharmacology , receptor , biochemistry , nitric oxide
Summary We investigated the role of insulin‐like growth factor‐1 ( IGF ‐1) in spontaneously hypertensive rats with erectile dysfunction. Firstly, we evaluated intracavernous pressure. The bioavailability of IGF ‐1 at both mRNA and protein levels were measured by quantitative real‐time PCR and Western blot respectively. Then, cavernous cyclic guanosine monophosphate concentrations were detected by enzyme‐linked immunosorbent assay. The cavernosal pressure was significantly decreased in the hypertensive and the propranolol treatment groups compared to the normal control group ( P < 0.01). Cavernous IGF ‐1 bioavailability and the concentrations of cavernous cyclic guanosine monophosphate were both significantly decreased in the hypertensive and the propranolol treatment groups compared to the normal control group ( P < 0.01). This study suggests that an obvious decrease in cavernous IGF ‐1 levels might play an important role in spontaneously hypertensive rats with erectile dysfunction.